BioSapien Nominated for 2026 Prix Galien Best Startup Award

San Diego, California, August 14, 2026

BioSapien Advances MediChip Toward Clinical Testing

BioSapien’s MediChip™ platform is designed as a localized, 3D-printed, slow-release drug-delivery system that can be attached to tissue. The technology is intended to deliver therapeutic agents directly within the tumor microenvironment, with the goal of increasing local drug exposure while potentially reducing systemic exposure and associated side effects. According to the company, localized delivery could allow more of an administered drug to remain near the tumor while using lower quantities of therapeutic agents. BioSapien believes this approach could support more targeted cancer treatment, potentially helping to reduce tumor burden, alleviate symptoms, and in some cases avoid or delay life-altering surgical procedures. The company is initially developing MediChip for colorectal cancer, with plans to explore potential applications in additional cancers, including pancreatic and lung cancers, as well as selected non-cancer indications. The platform’s ability to provide sustained local drug release is central to BioSapien’s development strategy. BioSapien is preparing to commence Phase I clinical trials in the United Arab Emirates, initially focusing on colorectal cancer patients. The upcoming first-in-human evaluation is expected to represent an important transition for the technology, moving its development from laboratory and platform work into clinical investigation.

Prix Galien Recognition Highlights Oncology Innovation

The Prix Galien USA Awards recognize innovation across the life sciences sector and are intended to highlight companies and technologies with the potential to advance human health. BioSapien has been shortlisted for the Best Startup category, placing the company among emerging organizations being considered for recognition in life sciences innovation. The 2026 awards ceremony is scheduled for October 29, 2026, at the American Museum of Natural History in New York City, where winners across the award categories are expected to be announced. BioSapien’s nomination arrives at a significant point in the company’s development. With MediChip moving toward first-in-human testing, the recognition provides visibility for its approach to localized cancer drug delivery while the company works toward generating clinical evidence. Dr. Khatija Ali, CEO and Founder of BioSapien, said the company aims to change how chemotherapy is delivered by increasing quality of life during cancer treatment and potentially reducing the need for major surgery. The nomination, according to BioSapien, recognizes the broader potential of its technology and its mission to develop new approaches to cancer care.

Localized Drug Delivery Targets Tumor Microenvironment

Conventional systemic cancer treatments distribute therapeutic drugs throughout the body, which can contribute to treatment-related toxicity. BioSapien’s MediChip is being developed around a different strategy: placing a slow-release drug-delivery device directly at the tissue site to concentrate treatment in the tumor microenvironment. The company’s platform is designed to be attachable to tissue while providing controlled release of therapeutic agents. This approach could potentially be applied across different tumor types and therapeutic compounds, although the clinical safety and effectiveness of MediChip remain to be established through human studies. BioSapien’s initial focus on colorectal cancer provides the first clinical pathway for evaluating the platform. Future expansion into pancreatic and lung cancers could broaden the technology’s potential applications if clinical development demonstrates sufficient safety and therapeutic benefit. The company emphasized that MediChip remains an investigational technology and is not yet an approved cancer treatment. Its potential benefits will need to be evaluated through appropriately designed clinical trials.

The Prix Galien nomination therefore represents a recognition of BioSapien’s innovation at an early clinical-development stage, while the upcoming Phase I program is expected to provide the first human data on the platform. Together, these developments position MediChip and localized oncology drug delivery as key components of BioSapien’s strategy to develop potentially more targeted approaches to cancer treatment.

Source: BioSapien press relese